KR102058420B1 - 데옥시콜산의 정제 방법 - Google Patents

데옥시콜산의 정제 방법 Download PDF

Info

Publication number
KR102058420B1
KR102058420B1 KR1020187014486A KR20187014486A KR102058420B1 KR 102058420 B1 KR102058420 B1 KR 102058420B1 KR 1020187014486 A KR1020187014486 A KR 1020187014486A KR 20187014486 A KR20187014486 A KR 20187014486A KR 102058420 B1 KR102058420 B1 KR 102058420B1
Authority
KR
South Korea
Prior art keywords
compound
dca
solution
purity
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020187014486A
Other languages
English (en)
Korean (ko)
Other versions
KR20180059568A (ko
Inventor
로버트 엠. 모리아티
존 그레고리 레이드
주니어 로이 에이. 스와링겐
Original Assignee
알레간 세일즈, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알레간 세일즈, 엘엘씨 filed Critical 알레간 세일즈, 엘엘씨
Publication of KR20180059568A publication Critical patent/KR20180059568A/ko
Application granted granted Critical
Publication of KR102058420B1 publication Critical patent/KR102058420B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187014486A 2009-12-18 2010-12-17 데옥시콜산의 정제 방법 Expired - Fee Related KR102058420B1 (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US28813209P 2009-12-18 2009-12-18
US61/288,132 2009-12-18
US30200710P 2010-02-05 2010-02-05
US61/302,007 2010-02-05
US30381610P 2010-02-12 2010-02-12
US61/303,816 2010-02-12
GB1008726.0 2010-05-25
GB1008726A GB2480632A (en) 2010-05-25 2010-05-25 Preparation of 12-keto and 12-alpha-hydroxy steroids
US34868610P 2010-05-26 2010-05-26
US61/348,686 2010-05-26
PCT/US2010/061150 WO2011075701A2 (en) 2009-12-18 2010-12-17 Methods for the purification of deoxycholic acid

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177011484A Division KR101862599B1 (ko) 2009-12-18 2010-12-17 데옥시콜산의 정제 방법

Publications (2)

Publication Number Publication Date
KR20180059568A KR20180059568A (ko) 2018-06-04
KR102058420B1 true KR102058420B1 (ko) 2019-12-24

Family

ID=42341289

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020187014486A Expired - Fee Related KR102058420B1 (ko) 2009-12-18 2010-12-17 데옥시콜산의 정제 방법
KR1020127017236A Expired - Fee Related KR101787719B1 (ko) 2009-12-18 2010-12-17 데옥시콜산의 정제 방법
KR1020177011484A Expired - Fee Related KR101862599B1 (ko) 2009-12-18 2010-12-17 데옥시콜산의 정제 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020127017236A Expired - Fee Related KR101787719B1 (ko) 2009-12-18 2010-12-17 데옥시콜산의 정제 방법
KR1020177011484A Expired - Fee Related KR101862599B1 (ko) 2009-12-18 2010-12-17 데옥시콜산의 정제 방법

Country Status (17)

Country Link
US (5) US20130137884A1 (https=)
EP (2) EP2513132B9 (https=)
JP (2) JP6393023B2 (https=)
KR (3) KR102058420B1 (https=)
CN (3) CN102812035A (https=)
AU (1) AU2010330760B2 (https=)
CA (1) CA2782478A1 (https=)
EA (2) EA031768B1 (https=)
ES (1) ES2575559T3 (https=)
GB (1) GB2480632A (https=)
IL (2) IL220225A0 (https=)
MY (1) MY167891A (https=)
NZ (1) NZ700195A (https=)
PH (1) PH12012501233A1 (https=)
SG (3) SG10201509046TA (https=)
WO (1) WO2011075701A2 (https=)
ZA (1) ZA201204388B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
GB2480632A (en) 2010-05-25 2011-11-30 Kythera Biopharmaceuticals Inc Preparation of 12-keto and 12-alpha-hydroxy steroids
MX363465B (es) 2011-02-18 2019-03-25 Kythera Biopharmaceuticals Inc Tratamiento de la grasa submental.
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
TWI572616B (zh) * 2011-06-16 2017-03-01 凱瑟拉生物製藥有限公司 去氧膽酸之組成物及用途及其相關方法
US20130102580A1 (en) * 2011-09-22 2013-04-25 Kythera Biopharmaceuticals, Inc. Compositions and methods related to deoxycholic acid and its polymorphs
WO2013044119A1 (en) * 2011-09-22 2013-03-28 Kythera Biopharmaceuticals, Inc. Compositions and methods related to deoxycholic acid and its polymorphs
CN104447929B (zh) * 2014-10-28 2016-06-29 湖南科瑞生物制药股份有限公司 一种合成3-羰基-4-雄烯-17β羧酸的方法
CN106146593B (zh) * 2015-04-14 2021-06-01 南京迈诺威医药科技有限公司 一种制备去氧胆酸的方法
CN106046093A (zh) * 2016-05-30 2016-10-26 华东师范大学 一种石胆酸的合成方法
JP7050008B2 (ja) * 2016-06-06 2022-04-07 クリスタル ファーマ，エセ．ア．ウ． デオキシコール酸の調製方法、およびデオキシコール酸の調製に有用な中間体
EP3511006B1 (en) * 2016-08-11 2021-08-04 Samsung Life Public Welfare Foundation Composition for preventing, improving or treating hair loss comprising deoxycholic acid as active ingredient
EP3645548B1 (en) 2017-08-03 2023-11-29 Medytox Inc. Methods for preparing bile acids
JP6899529B2 (ja) 2017-08-10 2021-07-07 パナソニックＩｐマネジメント株式会社 冷凍サイクル用作動媒体および冷凍サイクルシステム
CN114478676B (zh) * 2022-02-18 2024-05-10 国药集团化学试剂有限公司 一种脱氧胆酸钠的制备方法
CN116444597B (zh) * 2023-03-30 2025-03-28 南京迈诺威医药科技有限公司 一种制备去氧胆酸中间体和去氧胆酸的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US53446A (en) 1866-03-27 Improvement in cultivators
US2321598A (en) 1940-10-07 1943-06-15 George A Breon & Company Inc Preparation of desoxycholic acid
US2509248A (en) * 1947-09-05 1950-05-30 Merck & Co Inc Process for producing delta9, 11-3(alpha)-hydroxy-17-ketoetiocholene
GB695504A (en) 1950-10-18 1953-08-12 Drug Res Inc Method of isolating and purifying cholic and desoxycholic acids
GB716670A (en) 1951-06-19 1954-10-13 Armour & Co Improved process for purifying desoxycholic acid from contaminating cholic acid
US2651643A (en) * 1951-06-19 1953-09-08 Armour & Co Purification of desoxycholic acid
US2891972A (en) 1952-08-19 1959-06-23 Drug Res Inc Process of separating desoxycholic acid from mixed crude bile acids or salts thereof
US3533908A (en) 1967-05-19 1970-10-13 Brown Co Porous paperboard sheet having plastic microspheres therein
IT1202370B (it) 1976-07-12 1989-02-09 Hoffmann La Roche Soluzioni inietabili in cui l'atti vita' emolitica degli agenti di formazione di micelle naturali e' evitata mediante l'aggiunta di lipoidi e relativi prodotti
FR2446293A1 (fr) 1978-12-11 1980-08-08 Roussel Uclaf Procede de purification de l'acide chenodesoxycholique
IT8167097A0 (it) 1981-01-26 1981-01-26 Unilever Nv Composizione cosmetica per il trattamento della pelle o dei capelli
ES2033516T3 (es) 1988-04-08 1993-03-16 Roussel-Uclaf Procedimiento para preparar 9 alfa-hidroxi-17 metileno-esteroides.
US5085864A (en) 1989-10-30 1992-02-04 Abbott Laboratories Injectable formulation for lipophilic drugs
CA2033725C (en) 1990-01-24 2001-05-29 Folker Pittrof Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
ATE324897T1 (de) 1994-07-25 2006-06-15 Nda Int Inc Verwendung von noribogain derivaten zur behandlung von chemischer abhängigkeit bei säugern
US20020107291A1 (en) 1997-05-26 2002-08-08 Vincenzo De Tommaso Clear, injectable formulation of an anesthetic compound
IL123998A (en) 1998-04-08 2004-09-27 Galmed Int Ltd Conjugates of bile salts and pharmaceutical preparations containing them
US6417179B1 (en) 1998-10-13 2002-07-09 Craig G. Burkhart Ear wax solution
JP2002536415A (ja) * 1999-02-12 2002-10-29 セルパス インコーポレイテッド 抗腫瘍療法
EP1255566A2 (en) 2000-02-04 2002-11-13 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
EP1404700A2 (en) * 2001-05-22 2004-04-07 Inflazyme Pharmaceuticals, Ltd. Process for the production of 6,7-dihydroxy steroid compounds by allylic oxidation of steroid-5-ene compounds to steroid-5-ene-7-one compounds followed by hydroboration and oxidation and intermediates of this process
MXPA06013437A (es) 2004-05-19 2007-03-23 Los Angeles Biomed Res Inst Uso de un detergente para la eliminacion no quirurgica de grasa.
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US7754230B2 (en) 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
US20060222695A1 (en) 2005-04-01 2006-10-05 Filiberto Zadini Deoxycholic acid liposome-based dermatological topical preparation
CN101148468A (zh) 2006-09-19 2008-03-26 天津科技大学 以动物胆汁为原料高效提取胆红素和胆汁酸技术
AU2008209566C1 (en) * 2007-01-19 2013-02-14 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as TGR5 modulators and methods of use thereof
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
JOP20180077A1 (ar) * 2007-06-19 2019-01-30 Kythera Biopharmaceuticals Inc تركيبات وطرق لحمض صفراوي تخليقي
KR101916024B1 (ko) * 2007-06-19 2018-11-08 키쎄라 바이오파마슈티컬즈 인코포레이티드 합성 담즙산 조성물, 방법 및 제조물
HUE028327T2 (en) * 2008-06-06 2017-02-28 Neurmedix Inc A process for the preparation of 17-alkynyl-7-hydroxy steroids and related compounds
GB2480632A (en) 2010-05-25 2011-11-30 Kythera Biopharmaceuticals Inc Preparation of 12-keto and 12-alpha-hydroxy steroids
TWI572616B (zh) 2011-06-16 2017-03-01 凱瑟拉生物製藥有限公司 去氧膽酸之組成物及用途及其相關方法
US20130102580A1 (en) 2011-09-22 2013-04-25 Kythera Biopharmaceuticals, Inc. Compositions and methods related to deoxycholic acid and its polymorphs

Also Published As

Publication number Publication date
EA031768B1 (ru) 2019-02-28
SG10201803507YA (en) 2018-05-30
EP2513132B1 (en) 2016-03-09
WO2011075701A3 (en) 2012-07-26
EP2513132A2 (en) 2012-10-24
ES2575559T3 (es) 2016-06-29
US10005813B2 (en) 2018-06-26
US10981946B2 (en) 2021-04-20
KR101862599B1 (ko) 2018-05-31
IL261526A (en) 2018-10-31
CN102812035A (zh) 2012-12-05
ZA201204388B (en) 2013-07-31
EP3040342A1 (en) 2016-07-06
KR101787719B1 (ko) 2017-10-18
US20130137884A1 (en) 2013-05-30
KR20180059568A (ko) 2018-06-04
KR20120107982A (ko) 2012-10-04
EA201791511A1 (ru) 2018-03-30
US20200095274A1 (en) 2020-03-26
MY167891A (en) 2018-09-26
AU2010330760A1 (en) 2012-06-21
EA201290334A1 (ru) 2013-06-28
SG181768A1 (en) 2012-07-30
CN107011401A (zh) 2017-08-04
SG10201509046TA (en) 2015-12-30
AU2010330760B2 (en) 2015-01-22
JP6568025B2 (ja) 2019-08-28
GB201008726D0 (en) 2010-07-07
US20150141679A1 (en) 2015-05-21
GB2480632A (en) 2011-11-30
US9683007B2 (en) 2017-06-20
JP2013515006A (ja) 2013-05-02
IL220225A0 (en) 2012-07-31
PH12012501233A1 (en) 2012-11-05
JP6393023B2 (ja) 2018-09-19
CN106955287A (zh) 2017-07-18
US10472384B2 (en) 2019-11-12
NZ700195A (en) 2016-03-31
WO2011075701A2 (en) 2011-06-23
US20190135855A1 (en) 2019-05-09
JP2016193948A (ja) 2016-11-17
US20170320905A1 (en) 2017-11-09
KR20170049635A (ko) 2017-05-10
EP2513132B9 (en) 2017-12-27
EA035380B1 (ru) 2020-06-04
WO2011075701A4 (en) 2012-09-13
CA2782478A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
KR102058420B1 (ko) 데옥시콜산의 정제 방법
WO2013044119A1 (en) Compositions and methods related to deoxycholic acid and its polymorphs
TWI627180B (zh) 關於去氧膽酸及其多形體之組成物及方法
HK1226413A1 (en) Purified deoxycholic acid and its cosmetic use in the non-surgical removal of undesirable fat deposits
HK1226413A (en) Purified deoxycholic acid and its cosmetic use in the non-surgical removal of undesirable fat deposits
HK1241888A1 (en) Compounds and methods for the purification of deoxycholic acid
HK1241888A (en) Compounds and methods for the purification of deoxycholic acid
US3641005A (en) Process for the preparation of delta**4-6 6-difluoro - 320 - diketo - 17alp ha21-dihydr-oxypregnenes
US3255217A (en) 3beta-methoxy-androstane-16beta, 17beta-diol cycloborate

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

St.27 status event code: A-3-3-R10-R13-asn-PN2301

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

Not in force date: 20221218

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20221218

St.27 status event code: N-4-6-H10-H13-oth-PC1903